New Philips Minicare study, page-60

Myocardial infarction diagnosis in minutes: EU Project Lab 2Go starts
Feb 12th 2015

To save you the time, here's the google translation.

In cases of suspected acute myocardial infarction (AMI) is a rapid and reliable diagnosis is essential to improve survival and minimize late effects. Within the framework of the EU project "Lab-2-Go" examines a team ao.Univ.-Prof. Dr. John Mair at the University Clinic of Internal Medicine III (Cardiology and Angiology, (Director: Prof. Dr. Franz) clinical use an uncompleted property in developing point-of-care testing device for the rapid determination of troponin. I.
Cardiovascular diseases are the most common Todesursach represents over 65 year olds in the EU. Many patients with AMI come with chest pain symptoms to hospital. Currently, heart attacks, usually by means of electrocardiogram (ECG) and diagnosed the detection of myocardial injury in the patient's blood. However, many patients do not show the "typical" ST-segment elevation (so-called non-STEMI heart attacks) in the ECG. Especially in these cases, the laboratory diagnosis is correspondingly important.
Cardiac troponin I is a heart muscle-specific injury markers, ie this protein is found only in the heart muscle, and is rapidly released from damaged heart muscle within a few hours in the blood and is therefore considered more sensitive and reliable marker of heart muscle damage. The determination of this marker in the blood, which must be sent to the hospital laboratory, however, requires a certain amount of time, the test results is not earlier than 1 hour after blood collection before. Valuable time can be used for actual AMI patients thus pass by Waiting for lab test results, for example, up appropriate treatments are initiated or the patients are referred to appropriate specialized hospitals with cardiac catheterization laboratory. Secure myocardial infarction diagnosis within ten minutes of four European companies (Philips, Conworx Technology , Micro Systems Limited and Scienion) have developed in recent years a handy biophotonisches point-of-care instruments "mini Care". The small device is similar to a measuring device for determining the blood sugar levels at home. The great advantage of this system is that only one drop of blood is sufficient (the determination in capillary blood samples will be tested) to determine cardiac troponin-I. That is medical and para-medical personnel without special laboratory training could be so in the future in an instant in the ambulance or already in place, such as in the patients home, make a reliable diagnosis of myocardial damage. Time delays and special laboratory equipment, as previously required for the analysis of venous blood samples are thus omitted. "Lab-2-Go" Multicenter Study on Clinical Evaluation of "mini Care " Within the framework of the EU project "Lab-2Go" began in mid-January, the team ao. Univ.-Prof. Dr. John Mair at the Department of Internal Medicine III (Cardiology and Angiology) with a clinical trial to further the practicality and the technical improvement of the "mini Care" measuring system. Another six European, cardiological centers in France, Germany, Holland and the UK are involved in this multi-center study. The study results will provide the basis for further development and ultimately approval of the "mini Care" Diagnostic Systems in Europe and eventually worldwide.